Related by context. All words. (Click for frequent words.) 82 Completes Patient Enrollment 82 Receives Milestone Payment 80 Initiates Enrollment 79 Initiates Clinical Trial 79 Receive Milestone Payment 79 Meets Primary Endpoint 79 Presents Positive 79 Milestone Payment 79 Initiates Phase II 79 Submits NDA 79 Initiates Clinical 79 Receives Orphan Drug Designation 79 Presents Preclinical Data 79 Present Preclinical Data 78 Receives Approvable Letter 78 Phase 2a Trial 78 Submits Biologics License Application 78 Files IND 78 Licenses Novel 78 Initiates Phase III 78 Completes Enrollment 78 Patient Enrollment 78 Begins Dosing 78 Submits Response 77 Arthritis Drug 77 Reveals Positive 77 Lupus Drug 77 Phase 2b Trial 77 Epilepsy Drug 77 Phase 2b Clinical Trial 77 Therapeutic Competitors Companies 77 Gout Drug 77 Receives Complete Response 76 Reports Preclinical Data 76 Initiates Dosing 76 Initiate Phase III 76 Drug Fails 76 Receives Fast Track 76 Milestone Payments 76 Presents Preclinical 76 Enrolls First 75 Submits Supplemental 75 Oral Calcitonin 75 Novel Oral 75 NDA Submission 75 Announces Poster Presentations 75 Completes Dosing 75 Prostate Cancer Vaccine 75 Million Milestone Payment 75 Announces Tentative Approval 75 Vaccine Adjuvant 75 Q2 Loss Narrows 75 Drug Candidate 75 FDA Okays 75 Announce License Agreement 75 Schizophrenia Drug 75 Initiates Clinical Trials 75 Lung Cancer Drug 75 First Patient Enrolled 75 Blood Pressure Drug 75 JAK2 Inhibitor 75 Successfully Completes Phase 75 R MSCRAMM 75 Milestone Payment From 74 Drug Shows Promise 74 Develop Novel 74 Phase IIb Clinical Trial 74 FDA Accepts 74 Taro Receives 74 Mylan Receives Approval 74 IND Filing 74 Phase IIb Trial 74 Demonstrates Significant 74 Phase 1b Clinical Trial 74 Q2 Loss Widens 74 Receives Orphan Drug 74 Demonstrates Positive 74 Generic Versions 74 Announces Initiation 74 Gets FDA Clearance 74 Osteoporosis Drug 74 Files Investigational 74 Initiates Phase 2b 74 Preclinical Data 74 Provides Update Regarding 74 Q4 Loss Narrows 73 pralatrexate injection folate analogue 73 Phase III Clinical Trial 73 Collaborators Present 73 Rheumatoid Arthritis Drug 73 Announce Merger Agreement 73 Clinical Trial Results 73 Cholesterol Lowering Drug 73 Generic Version 73 Receives NASDAQ 73 Initiates Phase 73 FDA Approvals 73 BioSante Pharmaceuticals Announces 73 Launches Generic Version 73 Regains NASDAQ 73 Q1 Loss Narrows 73 Q3 Loss Narrows 73 Improves Survival 73 please visit http:/www.vandapharma.com 73 Cholesterol Drug 73 Inc. www.micromet inc.com 73 Migraine Drug 73 Expanded Indication 73 Psoriasis Drug 73 Inc. Nasdaq OXGN 73 Cites Positive 73 Phase III Trials 73 Terminate Merger Agreement 73 Files Shelf Registration Statement 73 Flamel Technologies Announces 73 Receives Notification 73 Demonstrates Sustained 73 please visit http:/www.atherogenics.com 73 Inhaled Insulin 73 FDA Clears 73 Xcytrin R 73 Settle Patent Litigation 73 Q1 Loss Widens 73 Achieves Primary Endpoint 73 Inc Therapeutic Competitors 72 Board Authorizes 72 Announce Collaboration Agreement 72 Collaborators Publish 72 Single Dose 72 Jumps Higher 72 Teva Provides Update 72 Announces Presentation 72 Pivotal Phase III 72 Novel Antibiotic 72 Q3 Loss Widens 72 Anti Tumor 72 Submits IND 72 Q4 Loss Widens 72 Pharma Merck Serono 72 Licenses Patents 72 Antitumor Activity 72 Employment Inducement Awards 72 Announces FDA Clearance 72 Aradigm Logo 72 Pivotal Phase 72 Initiate Clinical Trial 72 Receives Positive Opinion 72 Sinks Lower 72 IG HCR ;) CO 72 Phase III Trial 72 Antibody Drug Conjugate 72 Settles Litigation 72 Achieves Milestone 72 Invites Investors 72 CysDisplay R 72 Prolongs Survival 72 Initiate Phase 72 Nasdaq Deficiency Notice 72 Receives Tentative Approval 71 Significantly Improves 71 RNAi Therapeutics 71 Revises FY# Outlook 71 First Patient Dosed 71 Announces Dosing 71 STERIS Corporation Announces 71 Phase 2a Clinical Trial 71 Receives Favorable 71 Telik logo TELINTRA 71 FDA Approves Generic 71 Investigational Compound 71 Patent Covering 71 DARA logo 71 Genentech sanofi aventis 71 Confirmatory Phase 71 Announces Licensing Agreement 71 Restructures Operations 71 AVI BioPharma Announces 71 Therapeutic Competitors companiesandmarkets.com adEgemonye 71 Presents Positive Preclinical 71 Receives Notice From 71 Drug Combo 71 Immunomedics Announces 71 PRN FDA Approves 71 Sign Licensing Agreement 71 Investigational Treatment 71 sanofi aventis Bayer Schering 71 Investigational Oral 71 Extends Collaboration 71 Unsolicited Proposal From 71 Aeolus Pharmaceuticals Announces 71 Receives Unsolicited 71 Advanced Melanoma 71 Severe Sepsis 71 Merck OSI Pharmaceuticals 71 Settle Patent Dispute 71 Nasdaq VNDA 71 Namenda Memantine HCl 71 Demonstrates Potent 71 Biogen Genentech 71 Miraculins Announces 71 please visit http:/www.supergen.com 70 Voluntarily Withdraw 70 Previously Treated 70 Announces License Agreement 70 Strengthens Balance Sheet 70 Receives SFDA Approval 70 Combination REOLYSIN R 70 TRACON Pharmaceuticals 70 Reports Receipt 70 First Patient Treated 70 Dyax logo 70 Regains Compliance 70 4Q Loss Widens 70 Immunotherapeutic 70 Nasdaq AVNC 70 Testosterone Gel 70 developing adecatumumab 70 Announce Licensing Agreement 70 Transdermal Patch 70 novel emulsion formulation 70 Receives Anticipated 70 Oral Laquinimod 70 Generic Version Of 70 Shareholder Lawsuit 70 Announces Discontinuation 70 Corp. NASDAQ CYTR 70 TRANSDUR ® 70 Therapeutic Antibody 70 Generic Lovenox 70 markets HP Acthar 70 Combination Treatment 70 Regains Compliance With 70 VIVUS Announces 70 Receives CE Marking 70 Receives Tentative FDA 70 Boehringer Ingelheim MedImmune 70 Phase IIa Clinical Trial 70 pentadentate logo R 70 Heartburn Drugs 70 Granted Orphan Drug 70 Pharmacyclics Announces 70 Topline Results 70 Commences Phase 70 Regains Full 70 Nasdaq EPCT 70 Shows Promise Against 70 NewsBite Downgrade Puts Pressure 70 Webcast Presentations 70 Metastatic Melanoma 70 evaluating picoplatin 70 Completes Tender Offer 70 developing ACAPODENE 70 Extends Maturity 70 Hsp# Inhibitor 70 candidates Azedra TM 70 Begins Clinical Trial 70 Colaris Colaris AP 70 Vertex Pharmaceuticals Announces 70 Desvenlafaxine Succinate 70 Idenix Novartis 70 Receives Patent 70 Receives Commitment 70 Sign License Agreement 70 IND Application 70 MBRX 70 pharmacogenomic translational research 70 oncolytic virus therapies 70 Reduces Risk 70 Shows Promising 70 Unanimously Recommends Approval 70 Restructures Debt 70 developing ostarine selective 70 Diamyd Medical Diamyd 70 Anemia Drug 70 Announce Initiation 70 Identifies Potential 69 Files Patent Application 69 Expand Collaboration 69 Regeneron Pharma 69 FDA Panel Recommends 69 Protease Inhibitor 69 Reacquires 69 Awarded Qualifying Therapeutic 69 NASDAQ ENMD 69 Nuvelo Announces 69 Blood Thinner 69 Supplemental Biologics License Application 69 Amends Agreement 69 visit www.sciclone.com 69 Board Unanimously Rejects 69 Significantly Reduces 69 Extends Tender Offer 69 Enters Into Collaboration 69 Stockholders Approve Merger 69 Rotavirus Vaccine 69 Study Showed 69 Trial Evaluating 69 FDA Approves Novel 69 Receives FDA Clearance 69 Submits Application 69 Nasdaq XTLB 69 Backs FY# Outlook 69 Anti Tumor Activity 69 Underwriters Over Allotment 69 Posts Wider Loss 69 Demonstrates Potential 69 NASDAQ MNKD focuses 69 Mg Usa 69 Treatment Naïve 69 Guides Inline 69 Corp. AMEX CVM 69 Nasdaq Listing Requirements 69 Previously Disclosed 69 Purported Class 69 NMT Medical Announces 69 Projected Release Date 69 Shows Efficacy 69 lead molecular radiotherapeutic 69 Pending Acquisition 69 Alvine Pharmaceuticals 69 Explore Strategic Alternatives 69 Sign Definitive Merger 69 Lifts FY# Outlook 69 Reaffirms FY# Outlook 69 Provides Guidance 69 TM Aganocide 69 Data Suggest 69 Obtains Exclusive License 69 Pruvel TM 69 HCV Protease Inhibitor 69 visit http:/www.mannkindcorp.com 69 Improves Outcomes 69 Shareholder Claims 69 Brentuximab Vedotin SGN 69 3Q Loss Narrows 69 Inc. Nasdaq MITI 69 Inc EXEL 69 Hormone Refractory Prostate Cancer 69 Vicriviroc 69 Receives Notice Regarding 69 Study Evaluating 69 Patients Suffering 69 Nasdaq MNKD focuses 69 Transcept Pharmaceuticals 69 Pivotal Study 69 Announces Dismissal 69 2Q Loss Widens 69 please visit www.medicinova.com 69 Naglazyme R 69 Inc SPPI 69 Inflammatory Disease 69 SPRYCEL ® 69 Vaccine Protects Against 69 Amend Merger Agreement 69 please visit http:/www.sunesis.com 69 Tezampanel 69 Weight Loss Drug 69 Drug Maker 69 Statistically Significant 69 Taglich Brothers Initiates Coverage 69 Expands Scientific Advisory 68 Enters Into Licensing Agreement 68 Issued Patent 68 Posts Wider 4Q Loss 68 Successfully Completes Tender Offer 68 Q4 Profit Decreases 68 Enters Into Exclusive 68 Anticancer Compound 68 Systemic Delivery 68 Osteoporosis Drugs 68 Completes Reorganization 68 Key Milestones 68 Inc. Nasdaq TRMS 68 Receives Deficiency Letter 68 Myriad logo BRACAnalysis 68 Narrows 4Q Loss 68 Patent Expirations 68 PPD Declares 68 Receives Delisting Notification 68 microRNA Therapeutics 68 Treatment Naive Patients 68 Kaydon Corporation Announces 68 Nicotine Vaccine 68 Stockholders Approve Acquisition 68 Pegloticase 68 Welcomes Analyst Initiation 68 Fungal Infections 68 visit http:/www.PAREXEL.com 68 Anticancer Activity 68 RNAi Therapeutic 68 Terminates Merger Agreement 68 Commence Phase 68 Shingles Vaccine 68 Reaffirms Outlook 68 Aztreonam Lysine 68 Sunesis Pharma 68 Nasdaq PGNX 68 Sustained Reduction 68 PDL BioPharma Announces 68 Announces Favorable 68 Restate Financials 68 Poniard Pharmaceuticals Announces 68 Sangamo BioSciences Announces 68 VIVITROL ® 68 Vitrasert R 68 Evaluate Strategic Alternatives 68 Q2 Adj 68 Upcoming Deadline 68 Completes Previously Announced 68 Inc. NASDAQ MITI 68 Begins Shipment 68 TRANSDUR ™ 68 Novartis Novo Nordisk 68 Patients Treated With 68 Confirms Receipt 68 NYSE SCR Simcere 68 Anemia Drugs 68 Crofelemer budesonide foam 68 Receives Favorable Ruling 68 Phase 2b Study 68 Reduces Debt 68 LymphoStat B TM 68 Drug Coated Stent 68 Review Strategic Alternatives 68 Receives Delisting Notice 68 GATTEX TM 68 Nanophase Announces 68 Gene Therapy Trial 68 Treatment Reduces 68 markets COLAZAL 68 Anti Nausea 68 Pivotal Clinical Trial 68 Shown Effective 68 MSCRAMM ® 68 XL# anticancer compounds 68 Q1 Adj 68 Inc. NASDAQ SIRT 68 Q1 Profit Decreases 68 Disease Progression 68 Mutually Agree 68 Announces Stockholder Approval 68 Small Molecule 68 CoTherix logo 68 Improved Survival 68 Announce Settlement 68 Nasdaq CTIC 68 Merck Serono Nycomed 68 Secures Additional 68 molecular therapeutics immunotherapies 68 please visit www.dyax.com 68 Biomarker Study 68 Annual Meeting Date 68 NASDAQ XTLB 68 Nasdaq Delisting 68 Patent Lawsuit 68 Demonstrates Efficacy 68 Announce Licensing 68 NASDAQ Listing Requirements 68 Investigational Drug 68 FOLOTYN ® 68 Q4 Profit Soars 68 Reports Positive 68 Versus Placebo 68 Shareholder Lawsuit Against 68 Well Tolerated 68 Limb Ischemia 68 Q1 Profit Surges 68 FY# Loss Widens 68 Pooled Analysis 68 Awarded Patents 68 Viagra Soft Cialis Soft 68 Clinical Trial Data 68 Announces Positive 68 Pomerantz Law Firm 68 Abstract Accepted 68 Spectrum Pharmaceuticals Announces 68 Receives Approvals 68 Nasdaq Notice Regarding 68 Demonstrated Significant 68 Fast Track Status 68 Inc. Nasdaq IMGN 68 Isis Pharma 68 Reduces Workforce 68 Phase III Pivotal 68 Enlarged Prostate 68 Genentech Wyeth Pharmaceuticals 68 Awarded Patent 68 Explores Strategic Alternatives 68 Preclinical Models 68 Recombinant Protein 68 Company website www.anormed.com 68 Q2 Profit Surges 68 Strengthens Position 68 Q4 Profit Plunges 68 Reaffirms FY# Guidance 68 Expands Scope 68 Kinase Inhibitor 68 Receives Notice 68 Novel Therapeutic 68 Net Loss Widens 68 researches develops licenses 68 Posts Wider 67 Secures Financing 67 Patent Infringement Litigation 67 Liver Toxicity 67 Cholesterol Drugs 67 Broadens Its 67 Obtains Exclusive Rights 67 Treatment Shows Promise 67 Inc. Nasdaq SUPG 67 Geokinetics Announces 67 Dose Ranging 67 TriCo Bancshares Announces 67 DRRX 67 Commercialize Novel 67 Paris IPN Euronext 67 Novel Mechanism 67 Takeda Kyowa Hakko Kirin 67 Statin Drugs 67 OTC BB PVCT 67 Unsolicited Tender Offer 67 Nasdaq DVAX 67 Clinical Trial Evaluating 67 ARIAD Announces 67 Metabolic Disorder 67 Successfully Treated 67 Gets Favorable 67 Bullish Technical Alert 67 Little Colds Decongestant Plus 67 product platforms AZX# 67 Signs License Agreement 67 R lenalidomide 67 Nasdaq MNKD focused 67 Signs Merger Agreement 67 Vasogen Announces 67 NASDAQ VRUS 67 Licensing Pact 67 Inc. ProMetic www.prometic.com 67 visit http:/www.neogenomics.org 67 Private Equity Financing 67 Provides Shareholder 67 Ebola Vaccine 67 Oral Fingolimod 67 Plaque Psoriasis 67 Recombinant Human 67 Randomized Trials 67 Bush Embraces Pause 67 visit www.genenews.com 67 Factor Xa Inhibitor 67 Fewer Side Effects 67 MKC# MT 67 By JAMAAL ABDUL 67 PHRM 67 Pivotal Trial 67 Files Shelf Registration 67 Backs FY# View 67 Survival Benefit 67 Appears Safe 67 Purchase CIALIS Need 67 Therapeutic Vaccine 67 proprietary intravenous formulation 67 candidate MyVax 67 pipeline ImmunoGen collaborators 67 NexMed Receives 67 Slows Progression 67 HDAC Inhibitor 67 Epilepsy Drugs 67 Prostate Cancer Patients 67 Treatment Experienced 67 Earnings Postmortem 67 Announce Early Termination 67 programs visit http:/www.bionovo.com 67 Gene Variants 67 Restate Results 67 Settle Litigation 67 Inc. NASDAQ VSGN 67 Completes Transaction 67 DOR BioPharma Announces 67 Demonstrates Ability 67 Ondansetron Orally Disintegrating Tablets 67 Showed Significant 67 Begin Clinical Trials 67 Lowers Guidance 67 Dose Escalation 67 Receives Notice Related 67 Nanoemulsion 67 Regains Nasdaq 67 Medicure Announces 67 pain relievers Duragesic 67 Slow Progression 67 1Q Loss Widens 67 Anti Inflammatory 67 Recommends Approval 67 Randomized Phase II 67 Combo Therapy 67 Canaccord Genuity Maintains Hold 67 Adjunctive Therapy 67 Nasdaq AEGR 67 http:/www.cytrx.com 67 CNS Disorders 67 Cyclacel Pharmaceuticals 67 Sapacitabine 67 Updates Guidance 67 4SC AG ISIN DE# 67 INDICATED LOWER 67 Blood Thinning 67 Announces Publication 67 Ridaforolimus 67 Patients Receiving 67 Visit www.BASInc.com 67 Exercises Option 67 Closes Merger 67 Canaccord Genuity Reiterates Buy 67 Bullish Average Crossover 67 Acne Drug 67 candidate deforolimus 67 Revises Guidance 67 Announces Definitive Merger 67 Adjuvant Treatment 67 var arrUrl = 67 PDUFA Date 67 Reports Inducement Grants 67 JAK Inhibitor 67 developing Bicifadine serotonin 67 Trastuzumab DM1 67 Shows Statistically Significant 67 Nasal Powder 67 Cocaine Addiction 67 Cephalon GlaxoSmithKline 67 Cell Transplants 67 Synthetic Peptide 67 Prove Effective 67 AMEX KAL 67 Aurora Kinase 67 GNSZ 67 Resistant Hypertension 67 Wins Patent Infringement 67 Adopts Stockholder Rights 67 Beats Raises Guidance 67 Ecallantide 67 Announces Organizational Changes 67 Stock Soars 67 Lowers Risk 67 ATRA IV 67 motexafin gadolinium Injection 67 proprietary intranasal insulin 67 FDA APPROVES 67 Introduces Novel 67 Diabetic Foot Ulcer 67 CEFF financings subject 67 Enzon Pharmaceuticals Inc 67 Patent Infringement Suit Against 67 Grants Orphan Drug 67 please visit www.middlebrookpharma.com 67 Reminds Shareholders 67 ANDA Filing 67 successfully commercialize Iluvien 67 CFO Resigns 67 Underwriters Exercise 67 REG1 Anticoagulation System 67 Nasdaq ENMD 67 TRIOLEX ™ 67 var arrMeta = 67 novel orally inhaled 67 inflammatory PDE 67 Terminates Agreement 67 Hematology Molecular Pathology 67 Newly Identified 67 Subsidiary Enters 67 Inhaled Corticosteroids 67 Proxy Proposals 67 commercializing Loramyc ® 67 Shares Soar 67 Nasdaq ZGEN 67 Mg Uk 67 Receives Subpoena 66 Daytradersdigest.com 66 Obtains FDA 66 AN# topical anti 66 LGND 66 Restate Financial 66 Javelin Pharma 66 website www.celsion.com 66 Previously Announced 66 Nasdaq Minimum Bid 66 Polymerase Inhibitor 66 SIX RO ROG 66 milnacipran HCI 66 Fentanyl Patch 66 Disease Modifying 66 Nasdaq ACAD 66 Oral Suspension USP 66 Submits Investigational 66 Osteoporosis Treatment 66 Announces Successful Completion 66 Two Upcoming Investor 66 Agonist MABA program 66 estrogen receptor beta agonist 66 Announces Underwriters Exercise 66 Files Voluntary 66 markets Testim ® 66 palonosetron hydrochloride Injection Dacogen 66 Company NASDAQ SKBI 66 particularly SANCTURA XR 66 Vaccine Candidate 66 Antidepressant Drug 66 Significantly Reduced 66 ASE SVA 66 Q2 Profit Decreases 66 Completes Merger With 66 Cervical Cancer Vaccine 66 Narrows Guidance 66 MEK Inhibitor 66 Glatiramer Acetate 66 Bone Fracture 66 Monoclonal Antibody 66 Nasdaq CYTX 66 Demonstrate Significant 66 Q3 Profit Soars 66 Announces Consummation 66 Orally Active 66 Ups Guidance 66 Tumor Growth 66 Jointly Announce 66 Settles Patent Litigation 66 AAG geldanamycin analog 66 Reiterates FY# Outlook 66 Underwritten Public 66 Patent Lawsuit Against 66 Q4 Profit Surges 66 developing Zerenex ferric 66 Therapeutic Competitors 66 Inc. NASDAQ AGIX 66 Liver Damage 66 Painkiller Abuse 66 Announces Definitive Agreement 66 ALLOS THERAPEUTICS 66 Antibody Discovery 66 Vaccine Prevents 66 Humanized Anti 66 R memantine HCl 66 Enters Definitive Agreement 66 Preclinical Study 66 Atripla combines 66 Receives Stockholder Approval 66 Amends Credit 66 Patents Covering 66 Amgen Bayer Schering 66 Patent Issued 66 recurrent metastatic ovarian cancer 66 Anticancer Agent 66 HIV treatments Reyataz 66 Inc. NASDAQ TRGT 66 Files Patent 66 Issues Guidance 66 topical antifungal product 66 Receives Conditional 66 Wins Summary Judgment 66 Pivotal Trials 66 Univest Corporation Declares 66 Announces Ticker Symbol 66 Clinical Study Shows 66 4Q Profit Surges 66 Extend Collaboration 66 Tech DVAX 66 Sagent Pharmaceuticals Announces 66 Veronate R 66 Significantly Improved 66 Antipsychotic Drugs 66 Successfully Completes Acquisition 66 website http:/www.celsion.com 66 J.P. Morgan Healthcare 66 DYAX 66 Smallpox Vaccine 66 Clinical Trial Enrollment 66 Obtains License 66 Q3 Adj 66 Resubmits 66 Pulmonary Arterial Hypertension 66 PEGylated docetaxel 66 4Q Loss Narrows 66 Generic Protonix 66 Inc. NASDAQ TRMS 66 HCV RNA polymerase 66 Underwriters Exercise Over Allotment 66 manufactures minimally invasive 66 FDA Warns 66 Alnylam Nasdaq ALNY 66 CYT# potent vascular disrupting 66 Recurrent Glioblastoma 66 Seek Shareholder Approval 66 Announces Adjournment 66 Is Well Tolerated 66 Vitamin D analogue 66 Acute Attacks 66 Tyrosine Kinase Inhibitor 66 Closes Previously Announced 66 NICE Recommends 66 Bearish Average Crossover 66 Onyx Pharmaceuticals Announces 66 Proposed Buyout 66 Demonstrates Statistically Significant 66 Commences Phase III 66 Nasdaq HALO 66 Corp EPCT 66 Arno Therapeutics 66 Delays Filing 66 Anthracycline 66 Shareholders Approve Acquisition 66 ELADUR ™ 66 ® decitabine 66 Risperidone Oral Solution 66 Treated Patients 66 Shows Promise 66 Accelerate Commercialization 66 Complicated Skin 66 Transgenomic Pharmacogenomics Services 66 Consummates 66 Daiichi Sankyo Eli Lilly 66 Bone Metastases 66 FDA Approves Drug 66 http:/www.nastech.com 66 Personalized Immunotherapy 66 Vioxx Suits 66 Diabetic Nephropathy 66 Carboplatin Paclitaxel 66 ELADUR TM 66 Other ImmunoGen collaborative 66 PharmaVitae Profile 66 Files Provisional 66 Gets Bearish Confirmation 66 Antiangiogenic 66 visit www.targanta.com 66 XP# XP# 66 NOVAVAX 66 Preterm Labor 66 ENZN 66 MEMY 66 Cholesterol Lowering 66 MONSTERSTOX.COM Monsterstox.com 66 visit www.PAREXEL.com 66 Inc FRX FRX 66 Amends Stockholder Rights 66 Approve Merger 66 MCSP respectively 66 Calls Purchased 66 Provides Comprehensive 66 Unfractionated Heparin 66 Hematological Malignancies 66 Cellegy Pharmaceuticals 66 Authorizes Additional 66 Million Convertible Debt 66 Announce Definitive Agreement 66 Declares Dividend Increase 66 Becomes Effective 66 Randomized Phase 66 Rigel R# 66 Successfully Closes 66 Q2 Profit Plunges 66 Q3 Profit Surges 66 agonistic human 66 Oral Formulation 66 Inc FRX 66 candidate Hematide TM 66 Medisorb ® 66 Potentially Fatal 66 Inc. NASDAQ ICGN 66 Aloprim TM allopurinol sodium 66 please visit www.sucampo.com 66 Through Glycoscience R 66 technology visit http:/www.genmab.com 66 Naive Patients 66 Cephalon GlaxoSmithKline Schering Plough 66 Receives Positive 66 Ceflatonin R 66 Q4 Profit Declines 66 commercializing oxidized glutathione 66 Confirms Filing 66 Cardium Therapeutics TM 66 Advanced Prostate Cancer 66 Study Demonstrates 66 USOTC SSWC 66 Breast Cancer Recurrence 66 NASDAQ AVNR 66 Tomorrow Cures 66 Amex KAL 66 Phase III Clinical Trials 66 Posts 4Q Profit 66 StaphVAX R 66 Changes Ticker Symbol 66 Novel Compound 66 Effectively Treats 66 Patient Enrolment 66 Cutaneous T 66 Outlines Strategy 66 Initiates Voluntary Recall 66 Xoma Ltd 66 Complete Merger 66 targeted anticancer biopharmaceuticals 65 Lorus Therapeutics Announces 65 Nasdaq IMGN 65 Predict Risk 65 advanced compound INCB# 65 Receives Clearance 65 Aethlon Medical Releases 65 Lung Cancer Trial 65 DNA methyltransferase inhibitors 65 includes TOLAMBA TM 65 novel MetAP 2 65 Positive Opinion 65 Novartis Organon 65 Expands Portfolio 65 Completes Patient Enrolment 65 Node Positive 65 Drug Prevents 65 Relapsed Multiple Myeloma 65 Rheumatoid Arthritis Patients 65 HuCAL GOLD R 65 Inhaled Nitric Oxide 65 Telik Announces 65 including eniluracil ADH 65 Empatic ™ 65 apoptosis inducer 65 2Q Loss Narrows 65 #.#B Vioxx 65 Prophylactic Treatment 65 Settles Patent Infringement Lawsuit 65 Appoints Seasoned 65 acetonide FA 65 platform HDL Mimetic 65 Romidepsin 65 Patent Infringement Lawsuit 65 commercialize CorMedix drug 65 Bullish Speculation 65 LWLG 65 Nasdaq UNIS 65 Significantly Increases 65 PEG irinotecan 65 Puts Purchased 65 Successfully Concludes 65 Winmark Corporation Announces 65 Achieves Positive 65 Introduces Expanded 65 non nucleoside HCV 65 Arthritis Drugs 65 NASDAQ ADLR 65 AdvanSource Biomaterials Announces 65 Nicotine Conjugate Vaccine 65 Nasdaq SGEN 65 Aflibercept 65 Skymark Research Initiates Independent 65 Renal Cancer 65 pan histone deacetylase 65 EntreMed Presents 65 Regulatory Clearance 65 NOTE POSIDUR ™ 65 Blood Clotting 65 visit www.genmab.com 65 Frazer Penn. based 65 Aganocide 65 Treat Heart Failure 65 ALTROPANE R 65 Preliminary Injunction Against 65 subsidiaries visit http:/www.apricusbio.com 65 Low Doses 65 XL# XL# 65 SulphCo Announces 65 Discontinues 65 Bradmer Pharmaceuticals 65 Bearish Speculation 65 AnaSpec Introduces 65 CD# CEA 65 Exploring Strategic Alternatives 65 Therapeutic Competitors Report 65 Voluntarily Withdraws 65 telomerase therapeutic 65 novel antimitotic agent 65 Sitebrand Announces 65 Q2 Profit Declines 65 Announce Expiration 65 SAR# [002] 65 Declares Qtr 65 SABESP Announces 65 includes Dideco CarboMedics 65 Announces Definitive Agreements 65 NASDAQ SCRX specialty 65 Settles Patent Dispute 65 non nucleoside inhibitor 65 Patent Infringement Suit 65 Vaccine Shows Promise 65 please visit www.eisai.com 65 2 methoxyestradiol 65 Closes Over Allotment 65 Migraine Treatment 65 TKB# 65 Attracting Bullish Investors 65 Cancer Treatments 65 Exelixis logo 65 Zegerid OTC